Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.65 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.65 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.65 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.65 |
| ▸ | BCL9 | O00512 | 4/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347410 | 0.86 | TPSAB1 (0.70) | TPSAB1TPSD1TPSG1GRIN2BSMN1; SMN2 | |
| SCHEMBL5353748 | 0.86 | TPSAB1 (0.70) | TPSAB1TPSD1TPSG1GRIN2BSMN1; SMN2 | |
| SCHEMBL5348136 | 0.86 | TPSAB1 (0.70) | TPSAB1TPSD1TPSG1GRIN2BSMN1; SMN2 | |
| SCHEMBL5346990 | 0.83 | TPSAB1 (0.70) | TPSAB1TPSD1TPSG1GRIN2BSMN1; SMN2 | |
| SCHEMBL618588 | 0.83 | SMN1; SMN2 (0.71) | TPSAB1TPSD1TPSG1GRIN2BSMN1; SMN2 | |
| SCHEMBL5352959 | 0.82 | TPSAB1 (0.68) | TPSAB1TPSD1TPSG1GRIN2BSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23301123 | 0.82 | SMN1; SMN2 (0.69) | TPSAB1TPSD1TPSG1GRIN2BSMN1; SMN2 | |
| SCHEMBL13439706 | 0.79 | GRIN2B (0.61) | GRIN2BBCL9CTNNB1SMN1; SMN2CYP2C19 | |
| SCHEMBL542953 | 0.79 | GRIN2B (0.55) | GRIN2BBCL9CTNNB1SMN1; SMN2CYP2C19 | |
| SCHEMBL5366641 | 0.79 | TPSAB1 (0.68) | TPSAB1TPSD1TPSG1GRIN2BBCL9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100567293-C | Non-aryl-heterocycle NMDA/NR2B antagonist that N-replaces | MERCK & CO INC (US) | 2009-12-09 | — | — | CN | disclosed |
| US-7259157-B2 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-7217716-B2 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7053089-B2 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1379520-B1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1390034-A4 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040209889-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME CORP. | 2004-10-21 | — | — | US | disclosed |
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | ALLEN CHRISTOPHER (US) | 2004-10-14 | — | — | US | disclosed |
| EP-1399160-A4 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO INC (US) | 2004-08-25 | — | — | EP | disclosed |
| CN-1503793-A | N-substituted non-aryl-heterocyclic NMDA/NR2B antagonists | — | 2004-06-09 | — | — | CN | disclosed |
| EP-1399160-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | Merck & Co., Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1390034-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1379520-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK SHARP & DOHME CORP. | 2003-06-26 | — | — | US | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK SHARP & DOHME LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209889-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | GRIN1, GRIN2B, GRIN2A | TPSAB1 2573/4885TPSD1 2622/4885TPSG1 3747/4885 |
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | HTR1B, HTR2B, HTR1A | TPSAB1 133/4885TPSD1 307/4885TPSG1 386/4885 |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | GRIN1, GRIN2B, GRIN2A | TPSAB1 2199/4885TPSD1 2227/4885TPSG1 3949/4885 |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | GRIN1, GRIN2B, GRIN2A | TPSAB1 2566/4885TPSD1 2410/4885TPSG1 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.